Obstructive sleep apnea

Audience: Patients and providers
Status: Clinical guide · patient + provider
Last updated: 2026-03-27

1. Clinical overview

Obstructive sleep apnea is recurrent upper-airway collapse during sleep that drives intermittent hypoxia, sleep fragmentation, daytime impairment, and higher cardiovascular and metabolic risk.

2. Common causes and risk factors

Obesity, craniofacial crowding, male sex, advancing age, and sedative exposure are common risk factors.
Hypertension, atrial fibrillation, heart failure, diabetes, and resistant fatigue syndromes often coexist.

3. Typical symptoms

Loud snoring, witnessed apneas, daytime sleepiness, nonrestorative sleep, morning headache, and poor concentration.

4. Diagnosis and evaluation

Screen for sleepiness, driving risk, bed-partner observations, and cardiometabolic comorbidities.
Use guideline-based sleep testing and severity classification when suspicion is high.
Review nasal obstruction, alcohol/sedative burden, and sleep schedule contributors.

5. Treatment (non-pharmacologic)

Weight management, positional strategies, alcohol moderation, and sleep hygiene can reduce burden.
Treat nasal symptoms or congestion that undermine PAP adherence.

6. Treatment (pharmacologic)

There is no routine medication that directly treats OSA itself; PAP therapy remains the main treatment in many moderate to severe cases.
Weight-loss medications such as semaglutide or tirzepatide may improve OSA burden indirectly when obesity is a major driver.
Wake-promoting agents such as modafinil, armodafinil, or solriamfetol may be considered only for selected patients with residual daytime sleepiness after primary OSA treatment is optimized.

7. Monitoring and follow-up

Review device adherence, residual symptoms, mask fit, blood pressure, and daytime function.
Early follow-up improves long-term PAP success.

8. Practical counseling points

Explain that treatment reduces more than snoring; it also targets safety, BP, and cardiometabolic risk.
Troubleshoot comfort barriers early rather than letting adherence fail silently.
Reinforce caution with drowsy driving.

9. Red flags and escalation

Escalate when severe daytime somnolence creates safety risk, nocturnal hypoxemia is severe, or cardiorespiratory comorbidity is unstable.
Seek sleep specialist input for persistent symptoms despite adherence or unclear testing results.

10. Guideline references

American Academy of Sleep Medicine guidance.
ACC/AHA and AF guidance where OSA affects cardiovascular risk.
Obesity and sleep-medicine best practices for long-term management.

Note: Educational guide only; not a substitute for individualized medical care.